To evaluate whether EMP2 is a better target for distinguishing breast cancer cells, some studies on breast cancer cell lines used an anti-EMP2 monoclonal antibody to capture MCF-7 and MDA-MB231 breast cancer cells. Here, EMP2 is linked to breast carcinoma.